Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 7,685

Document Document Title
WO/2022/166749A1
Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...  
WO/2022/166991A1
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.  
WO/2022/167002A1
Disclosed is a 1,4-sulfobridged polycyclic compound containing a dihydrobenzofuran structure, belonging to the field of organic synthesis, and having a structure as shown in formula (I). Further disclosed is a preparation method therefor...  
WO/2022/106469A3
The present invention provides compounds of formula (I), for the treatment of an infection in warm-blooded animal caused by endoparasites, more preferably a helminthic infection, even more preferably a heartworm infection. Exemplary comp...  
WO/2022/159746A1
Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).  
WO/2022/157166A1
The present invention relates to a group of compounds of formula (I) which are inhibitors of the Discoidin Domain Receptors (DDR1/2), whose overexpression is produced in several diseases such as cancer, pulmonary fibrosis, cirrhotic live...  
WO/2022/159436A1
Provided is a compound, including a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and if W is a direct bond, then X1, X2, X3, and X4 are each independentl...  
WO/2022/152316A1
A biphenyl derivative, a preparation method therefor and the use thereof in the preparation of a medicine for treating related diseases. In particular, the present application relates to a compound represented by formula (I) and a pharma...  
WO/2022/150920A1
The present application relates to the treatment of plant nematode infections. For example, the application relates to the use of one or more compounds of Formula (I) as defined herein, or compositions comprising these compounds, for tre...  
WO/2022/150316A1
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.  
WO/2022/150574A1
Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.  
WO/2022/148434A1
Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.  
WO/2022/147302A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2022/135572A1
A compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method ther...  
WO/2022/138987A1
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...  
WO/2022/138833A1
The present invention provides a photoelectric conversion element which is reduced in the electric field intensity dependency of a photoelectric conversion efficiency. The present invention also provides an imaging element, an optical se...  
WO/2022/140527A1
The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.  
WO/2022/140144A1
Disclosed are various synthetic methods to prepare structural analogs of largazole and derivatives thereof. One structural analog is an amide isostere of largazole. Another structural analog replaces the thiazole ring of largazole with a...  
WO/2022/136509A1
The disclosure is directed to compounds of formula (I),and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.  
WO/2022/139249A1
The present invention relates to a polysubstituted imidazole[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by...  
WO/2022/131869A1
The present invention provides a novel compound and an organic light-emitting device comprising same.  
WO/2022/130238A1
A new process for the synthesis of amide derivatives of 8-hydroxypenicillanic acid is described, more specifically starting from amide derivatives of the 6-aminopenicillanic nucleus protected as tert-butylcarbamate.  
WO/2022/131757A1
The present invention provides a novel compound and an organic light emitting device comprising same.  
WO/2022/133345A1
Compounds with KRAS G12C inhibitory activity are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation. Preferably the compounds fall within formula (I).  
WO/2022/129331A1
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseas...  
WO/2022/133064A1
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions th...  
WO/2022/125849A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).  
WO/2022/117473A1
The present invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2022/115400A1
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound IA, wherein R1 is described herein. Compound IA can be useful in sy...  
WO/2022/105930A1
The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING act...  
WO/2022/109573A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...  
WO/2022/108354A1
The present invention provides a novel compound, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an antibiotic composition compri...  
WO/2022/106469A2
The present invention provides compounds of formula (I) which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.  
WO/2022/100717A1
Disclosed are a leukocyte classification reagent and kit, a classification method, an erythrocyte analysis reagent and kit, and an analysis method. Both the leukocyte classification reagent and the erythrocyte analysis reagent comprise a...  
WO/2022/100727A1
The present invention provides a novel class of imidazothiazole compounds as ATX (Autotaxin) inhibitors, a pharmaceutical composition comprising the compound, and a use of the compound and the composition to treat a mammal suffering from...  
WO/2022/099659A1
Provided are a leukocyte classification reagent, reagent kit, and classification method, and an erythrocyte analysis reagent, reagent kit, and analysis method. Each of the leukocyte sorting reagent and the erythrocyte analysis reagent co...  
WO/2022/089296A1
Disclosed are a thienopyrimidine compound, a pharmaceutical composition comprising same, and an application thereof. The thienopyrimidine compound has a structure represented by formula I. The compound interferes with the interaction bet...  
WO/2022/093856A1
The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain ...  
WO/2022/078971A1
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...  
WO/2022/078350A1
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.  
WO/2022/079290A2
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...  
WO/2022/076796A1
The present disclosure provides novel macrocyclic peptides which inhibit the PD- 1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.  
WO/2022/076794A1
The present disclosure provides novel macrocyclic peptides which inhibit the PD- 1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.  
WO/2022/076629A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis usi...  
WO/2022/036060A9
Crystalline forms of salts of Compound I are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.  
WO/2022/066805A1
A compound of Formula (I) is provided: where the variables are defined herein.  
WO/2022/063896A1
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...  
WO/2022/064075A1
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they ...  
WO/2022/064187A1
A compound of formula (I-1), or a pharmaceutically acceptable salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected fr...  
WO/2022/064459A1
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and...  

Matches 1 - 50 out of 7,685